FY2024 EPS Estimates for Disc Medicine, Inc. Lifted by Cantor Fitzgerald (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for Disc Medicine in a research note issued to investors on Wednesday, June 26th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($4.45) for the year, up from their prior estimate of ($5.12). Cantor Fitzgerald currently has a “Overweight” rating and a $85.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.56) per share.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09).

A number of other analysts have also commented on IRON. Wedbush reiterated an “outperform” rating and issued a $57.00 price objective (up from $43.00) on shares of Disc Medicine in a research report on Friday, June 14th. Morgan Stanley lowered their price objective on Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $70.00 price objective (up from $50.00) on shares of Disc Medicine in a research report on Monday, June 17th. Raymond James boosted their target price on Disc Medicine from $40.00 to $43.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Finally, Stifel Nicolaus boosted their target price on Disc Medicine from $71.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Disc Medicine currently has an average rating of “Moderate Buy” and a consensus target price of $62.57.

Disc Medicine Stock Up 1.6 %

Disc Medicine stock opened at $45.07 on Friday. The stock has a 50-day simple moving average of $35.07 and a 200 day simple moving average of $50.28. Disc Medicine has a 12-month low of $25.60 and a 12-month high of $77.60. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -13.33 and a beta of 0.51.

Insider Activity

In other news, Director William Richard White sold 2,560 shares of Disc Medicine stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $31.80, for a total transaction of $81,408.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.24% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors have recently bought and sold shares of IRON. Swiss National Bank bought a new stake in Disc Medicine in the 3rd quarter valued at approximately $817,000. Charles Schwab Investment Management Inc. raised its stake in shares of Disc Medicine by 309.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 84,200 shares of the company’s stock worth $3,956,000 after purchasing an additional 63,644 shares in the last quarter. Invesco Ltd. raised its stake in shares of Disc Medicine by 45.7% during the 3rd quarter. Invesco Ltd. now owns 161,213 shares of the company’s stock worth $7,574,000 after purchasing an additional 50,581 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Disc Medicine during the 3rd quarter worth approximately $782,000. Finally, Profund Advisors LLC bought a new stake in shares of Disc Medicine during the 3rd quarter worth approximately $496,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.